Get the Stockscreener App
91.94
1.87%
-1.755
After Hours:
91.94
0.005
+0.01%
Axsome Therapeutics Inc stock is traded at $91.94, with a volume of 789.30K.
It is down -1.87% in the last 24 hours and down -1.68% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$93.69
Open:
$94.02
24h Volume:
789.30K
Relative Volume:
1.27
Market Cap:
$4.37B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-14.08
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+14.85%
1M Performance:
-1.68%
6M Performance:
+9.79%
1Y Performance:
+7.55%
1-Day Range:
$91.81
$94.89
1-Week Range:
$80.98
$95.36
52-Week Range:
$64.11
$105.00
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
91.94 | 4.37B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
3,000 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Flower City Capital - MarketBeat
Zacks Research Issues Pessimistic Forecast for AXSM Earnings - MarketBeat
Axsome Asks FDA to Approve Questionable Alzheimer’s Agitation Drug - Being Patient
When Will Axsome Therapeutics, Inc. (NASDAQ:AXSM) Turn A Profit? - Simply Wall St
Axsome reports mixed results for Alzheimer's agitation drug - MSN
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $129.43 - MarketBeat
William Blair Has Positive Forecast for AXSM FY2024 Earnings - MarketBeat
William Blair Has Positive Estimate for AXSM FY2024 Earnings - MarketBeat
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last? - MSN
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Axsome’s 2024 Results Show Growth in Sunosi Sales and Progress for AXS-12 - Sleep Review
Pallas Capital Advisors LLC Purchases Shares of 26,435 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Truist raises Axsome Therapeutics target to $180, maintains Buy By Investing.com - Investing.com Canada
Objective long/short (AXSM) Report - Stock Traders Daily
Axsome Therapeutics (NASDAQ:AXSM) Shares Up 5.3% After Analyst Upgrade - MarketBeat
Axsome Therapeutics' (AXSM) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Axsome Therapeutics, Inc. Provides Preliminary Unaudited Total Product Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue - The Manila Times
Truist raises Axsome stock target to $180, maintains buy rating - Investing.com
Truist raises Axsome stock target to $180, maintains buy rating By Investing.com - Investing.com UK
JPMorgan Chase & Co. Raises Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
What is Zacks Research's Forecast for AXSM FY2024 Earnings? - MarketBeat
Excessive Daytime Sleepiness Clinical and Non-Clinical - openPR
Axsome Therapeutics (NASDAQ:AXSM) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook - Yahoo Finance
Axsome to seek approval of AXS-05 to treat agitation in... - Alzheimer's News Today
Axsome to lean on totality of data in Alzheimer’s agitation submission - BioCentury
Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome. - Barron's
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing - BioSpace
Axsome Therapeutics stock steady as Baird reiterates confidence in long-term prospects - Investing.com Canada
GLP-1 questions emerge for 2025 [Video] - AOL
Axsome shares boosted by strong Phase 3 outcomes and Buy rating reiteration - Investing.com Canada
These 13 Things Could Make You More Likely to Get Alzheimer's, According to Research - AOL
Short Interest in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Declines By 7.9% - MarketBeat
Leerink reiterates Outperform on Axsome stock despite FDA uncertainty for Auvelity - Investing.com Canada
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $122.00 at Mizuho - MarketBeat
Axsome Therapeutics Remains A Buy Despite AXS-05’s Mixed Results (NASDAQ:AXSM) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results - Benzinga
Axsome’s Alzheimer’s drug shows promise in trials By Investing.com - Investing.com Nigeria
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data - MedCity News
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation - Yahoo! Voices
Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains Bullish - MSN
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap DownHere's Why - MarketBeat
Smart Money Is Betting Big In AXSM Options - Benzinga
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data - Reuters.com
Axsome's Alzheimer's drug shows promise in trials - Investing.com India
Alzheimer's Agitation Drug Trial Data Mixed - Newsmax
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):